"We are pleased to have concluded this innovative transaction with Royalty Pharma."
John Gunn, Executive Vice President, Memorial Sloan-Kettering Cancer Center"Importantly, by monetizing only a portion of our royalty interest while still retaining a meaningful ongoing royalty interest in Neupogen®, we were able to better diversify MSKCC assets."
Michael Gutnick, Vice President Finance, Memorial Sloan-Kettering Cancer Center
At a Glance
Neupogen® (filgrastim) and Neulasta® (pegfilgrastim) are white blood cell stimulants used to prevent neutropenia in patients undergoing chemotherapy. Used for patients receiving a range of chemotherapy treatments, bone marrow transplants, peripheral blood progenitor cell collection and patients with neutropenia. Neulasta®, the pegylated version of Neupogen®, has longer half life, resulting in dosing advantages.
Amgen’s Neupogen® (filgrastim), or granulocyte colony stimulating factor, is a genetically-engineered version of a naturally occurring protein that is the body’s primary defense against bacterial infections by stimulating white blood cell production. Neulasta® has a longer half life, resulting in a dosing advantage. Neupogen® and Neulasta® are used to treat patients receiving a range of chemotherapies, bone marrow transplants, peripheral blood progenitor cell collection and patients with neutropenia.
Applications In Development:
January 2004 & August 2005